BridgeBio Pharma stock rating reiterated at Buy by TD Cowen

TD Cowen reaffirmed a Buy on BridgeBio Pharma with a $95 price target versus a $70.84 share price, implying roughly 34% upside. The firm said Pfizer's tafamidis settlement, with patent protection through June 2031 and up to six months of exclusivity, gives BridgeBio 7.5 to 8 years to grow Attruby before generic pressure matters. Analyst confidence has improved across the Street, with several firms reiterating positive ratings and targets of $100 to $111, while BridgeBio is also boosting ATTR-CM awareness through a national campaign.

Analysis

The key implication is not simply that BridgeBio gets a cleaner runway, but that the market can now underwrite a much longer period of monopoly-like economics for Attruby before the first real pricing compression shows up. That matters because biotech multiples often re-rate on duration of cash flow visibility more than on near-term sales prints; the de-risking of the patent overhang shifts the debate from binary litigation outcomes to execution, which is a much easier problem for the stock to absorb.

The second-order winner is likely not Pfizer, which absorbs the strategic erosion but can defer the full genericization drag for years; the bigger loser is any would-be fast follower that was counting on a near-term substitution window in the cardiology niche. If BridgeBio can use this extended window to build prescribing habits and expand diagnosis rates, the eventual generic entry could arrive into a materially larger market with a lower switching elasticity than sell-side models currently assume.

The contrarian risk is that investors may be extrapolating the litigation win into a straight-line valuation step-up, when the real bottleneck is commercialization. Awareness campaigns help at the margin, but they do not guarantee durable script acceleration; if uptake slows after the initial re-rate, the stock could give back gains even while the legal thesis remains intact. In other words, the overhang removal is a necessary condition for upside, not a sufficient one.

On timing, the next catalyst stack is measured in quarters, not days: prescription data, launch cadence, and any evidence that attruby is taking share in a larger-than-expected addressable pool. The most important reversal risk over 6-18 months is either an unexpectedly rapid competitive response from alternative therapies or a market realization that the TAM expansion rate is below current optimism. That would compress the multiple before any patent issue becomes economically relevant.

Key Decisions for Investors

• Go long BBIO on pullbacks over the next 1-3 weeks; use the litigation de-risking as a catalyst to own the stock ahead of the next quarterly prescription update, with a target of 15-20% upside and a stop if launch momentum fails to inflect.
• Buy BBIO Jan-2026 calls or call spreads to express duration on the de-risked exclusivity window; structure for limited downside and convex participation if the market starts capitalizing multi-year Attruby runway.
• Pair trade: long BBIO / short a basket of near-term patent-exposed biotech names facing generic overhangs, to isolate the benefit of extended cash-flow visibility versus names still priced for binary litigation risk.
• If already long, trim into strength after the first post-news re-rating; the trade becomes less attractive once the market fully prices the legal resolution and shifts focus to slower-moving launch metrics.
• For more defensive exposure, wait for the next 1-2 quarters of prescription data before adding size; the best risk/reward is after confirmation that awareness spend is converting into sustained utilization rather than one-off sentiment support.